Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and Carcinoma, Lobular

lapatinib has been researched along with Carcinoma, Lobular in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Bueno, C; Carolla, RL; Chen, B; Hillman, DW; Jenkins, RB; Johnson, DB; Leon-Ferre, RA; Moreno-Aspitia, A; Northfelt, DW; Perez, AT; Perez, EA; Zon, RT1
Fasching, PA; Gade, S; Loibl, S; Lübbe, K; Mau, C; Müller, V; Pantel, K; Schem, C; Schwarzenbach, H; Schwedler, K; Steinbach, B; Untch, M; von Minckwitz, G1
Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V1
Christgen, M; Dorssers, LC; Kreipe, H; Lehmann, U; Looijenga, LH; van Agthoven, T1
Bonnefoi, H; Grellety, T; Italiano, A; Robert, J; Soubeyran, I1
Bermejo, B; Cortés, J; de la Peña, L; Galván, P; Llombart-Cussac, A; López, R; Martínez, N; Morales, S; Muñoz, M; Nuciforo, P; Oliveira, M; Paré, L; Peláez, A; Pernas, S; Prat, A; Vidal, M1
Battelli, N; Bessi, S; Biganzoli, L; Buyse, M; Coombes, CR; Di Leo, A; Di Marsico, R; Gianni, L; Gori, S; Masci, G; Minisini, AM; Pestrin, M; Puglisi, F; Ravaioli, A; Stebbing, J; Tondini, C1

Trials

3 trial(s) available for lapatinib and Carcinoma, Lobular

ArticleYear
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
    Breast cancer research and treatment, 2020, Volume: 182, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab

2020
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab

2017
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
    Breast cancer research and treatment, 2012, Volume: 134, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Treatment Outcome

2012

Other Studies

4 other study(ies) available for lapatinib and Carcinoma, Lobular

ArticleYear
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Breast cancer research and treatment, 2014, Volume: 147, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Female; Follow-Up Studies; Humans; Lapatinib; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Translational Research, Biomedical; Trastuzumab

2014
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome

2015
Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Lobular; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Long Noncoding

2015
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1

    Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cadherins; Capecitabine; Carcinoma, Lobular; Female; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation, Missense; Quinazolines; Radiography; Receptor, ErbB-2; Treatment Outcome

2016